Clinical trial

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

NCT03782532

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-01-25

PhasePHASE3

Study timeline

Study start (actual)2019-01-25Date precision: day

Registry last updated2022-12-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

Dupilumab SAR231893DRUG

PlaceboDRUG

Asthma Controller Therapies (include prednisone/prednisolone)DRUG

Asthma Reliever TherapiesDRUG

Sponsors & collaborators

Sanofilead sponsor

Regeneron Pharmaceuticalscollaborator

Mapped research locations

ShanghaiChina7 HangzhouChina5 BeijingChina4 GuangzhouChina3 NanjingChina3 ChengduChina2 WuhanChina2 TianjinChina1 ChongqingChina1 ChangshaChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03782532 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.